LOGIN
ID
PW
MemberShip
2025-09-04 12:55
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Product
Mounjaro arrives at pharmacies..₩310,000–350,000
by
Kang, Hye-Kyung
Aug 21, 2025 06:07am
Mounjaro (tirzepatide), which had been attracting considerable attention even before its arrival in Korea, has now been made available to pharmacies. With prescriptions also beginning on the 20th, pharmacies are bustling with activity. According to local pharmacies, two dosage forms, 2.5mg and 5mg, have begun arriving at pharmacies through wh
Company
Nubeqa gains flexibility with indication expansion
by
Whang, byung-woo
Aug 21, 2025 06:06am
The influence of Nubeqa (darolutamide) is rising in the market with the company expanding its indication as a treatment for metastatic hormone-sensitive prostate cancer (mHSPC). Experts believe that the drug may settle as a flexible treatment option in Korea¡¯s market as it has broadened its path as a personalized treatment. With the approval
Company
Reimb of polycythemia vera drug 'BESREMi' likely in Sept
by
Eo, Yun-Ho
Aug 21, 2025 06:06am
The polycythemia vera treatment 'BESREMi' is expected to be listed on the national health insurance list. The National Health Insurance Service (NHIS) and PharmaEssentia Korea have recently reached a final agreement on the drug price negotiation for BESREMi (ropeginterferon alfa-2b). As a result, if it passes the Health Insurance Policy Re
Company
Viatris signs exclusive sales and distribution deal for Brid
by
Whang, byung-woo
Aug 21, 2025 06:05am
Viatris Korea announced on the 20th that it has signed an exclusive domestic promotion and distribution agreement for the general anesthesia reversal agent Bridion (Sugammadex) through a strategic partnership with MSD Korea. Under the agreement, Viatris Korea officially took over the domestic promotion and distribution of Bridion as of th
Company
Generics challenge the patent of mkt leading 'Rinvoq'
by
Kim, Jin-Gu
Aug 21, 2025 06:05am
The patent challenges by generics targeting AbbVie's Janus kinase (JAK) inhibitor' Rinvoq (upadacitinib)' have begun. The pharmaceutical industry anticipates that patent challenges will further expand as Rinvoq strengthens its monopolistic position in the JAK inhibitor market, which is valued at approximately KRW 62 billion annually.
Opinion
[Desk View] Can NHI alone cover the costs of cancer drugs?
by
Lee, Tak-Sun
Aug 20, 2025 06:23am
The reimbursement claim amount submitted for anti-cancer drugs has been increasing robustly every year. According to the '2024 Pharmaceutical Reimbursement Claims Data' published by the Health Insurance Review & Assessment Service, drug expenditure for cancer diseases in 2024 amounted to KRW 4.1372 trillion, a 7.4% increase from KRW 3.850
Opinion
[Reporter's View] Innovation exists in treating all diseases
by
Eo, Yun-Ho
Aug 20, 2025 06:23am
When discussing Korea¡¯s insurance reimbursement system, the qualifier ¡°life-threatening¡± has long been a source of frustration. It is no exaggeration to say that, for the pharmaceutical industry, this phrase has been the number one target for removal since the very beginning. This was the case in determining eligibility for the Risk Sh
Company
Expanded patent dispute over cancer drug 'Xtandi'
by
Kim, Jin-Gu
Aug 20, 2025 06:22am
The number of companies challenging the patent for Astellas' prostate cancer treatment, 'Xtandi (enzalutamide)', has expanded to six. Attention has been drawn to the fact that major pharmaceutical companies, such as Chong Kun Dang, Hanmi Pharmaceutical, and JW Pharmaceutical, have joined this latest patent challenge. According to the phar
Policy
MFDS's bill on stable supply of essential drugs in review
by
Lee, Jeong-Hwan
Aug 20, 2025 06:22am
A bill to add ¡°medicines that are essential for healthcare and require stable supply¡± and ¡°medicines with similar therapeutic effects with no alternative treatments¡± to the list of national essential medicines, thereby resolving the issue of unstable supply of medicines, is likely to pass the Health and Welfare Committee's legislative su
InterView
Dong-A ST launches Sterlara biosimilar Imuldosa in the US
by
Cha, Jihyun
Aug 20, 2025 06:22am
Dong-A ST (CEO: Jae-Hoon Jeong) announced on the 19th that the company has launched IMULDOSA (project name DMB-3115, active ingredient ustekinumab), a biosimilar version of Stelara, in the US through its partners, multinational pharmaceutical companies Intas Pharmaceuticals and Accord Biopharma. IMULDOSA is biosimilar version of Janssen¡¯
1
2
3
4
5
6
7
8
9
10
>